AbbVie Sales And Growth Increasingly Dominated By Humira
This article was originally published in The Pink Sheet Daily
Executive Summary
Since its split from Abbott Laboratories in January, AbbVie has been telling a story of gradually overcoming loss of revenue due to generic-challenged lipid franchise via Humira growth and a promising pipeline. For the first quarter of 2013, Humira generated worldwide sales of $2.244 billion, slightly more than half of the company’s entire revenue base.